Drug
Zeleciment Basivarsen
Zeleciment Basivarsen: highest development phase Phase 3, developed by Dyne Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Dyne Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| zeleciment basivarsen (DYNE-101) NCT07486934 | Phase 3 | Myotonic Dystrophy Type 1 (DM1) |
Latest
No recent events.
Follow Zeleciment Basivarsen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.